Singapore, May 27 -- Shanghai Pharmaceutical Group and Novartis, a global pharmaceutical giant, have officially signed a strategic cooperation agreement on a number of ophthalmic products in China.

In this cooperation, Novartis China will leverage the advantages of Shanghai Pharmaceutical Holdings' omni-channel integrated marketing services and extensive market coverage capabilities to accelerate the sinking of its mature anti-infective and glaucoma products to non-target market terminals, so that more patients can use high-quality drugs in a timely manner.

Relying on the brand influence and product advantages of Novartis China, and the excellent clinical effect and safety of these products, Shanghai Pharmaceutical Group has further imp...